Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 9/20 | 0.76 |
| ▸ | PIM1 | P11309 | 2/20 | 0.76 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.60 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.60 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.60 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | INSR | P06213 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | CSF1R | P07333 | 1/20 | 0.58 |
| ▸ | LYN | P07948 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | IGF1R | P08069 | 1/20 | 0.58 |
| ▸ | MET | P08581 | 1/20 | 0.58 |
| ▸ | ROS1 | P08922 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.58 |
| ▸ | FGR | P09769 | 1/20 | 0.58 |
| ▸ | KIT | P10721 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13234269 | 0.88 | FYN (0.80) | FYNPIM1NTRK1NTRK3NTRK2 | |
| SCHEMBL1053535 | 0.88 | FYN (0.80) | FYNPIM1NTRK1NTRK3NTRK2 | |
| SCHEMBL1051257 | 0.86 | PIM1 (1.00) | FYNPIM1NTRK1NTRK3NTRK2 | |
| SCHEMBL2943784 | 0.86 | FYN (1.00) | FYNPIM1NTRK1NTRK3NTRK2 | |
| SCHEMBL2943172 | 0.86 | FYN (0.69) | FYNPIM1NTRK1NTRK3NTRK2 | |
| SCHEMBL3189572 | 0.85 | FYN (0.62) | FYNPIM1NTRK1NTRK3NTRK2 | |
| SCHEMBL30521746 | 0.84 | FYN (1.00) | FYNPIM1IKBKB | |
| SCHEMBL2941291 | 0.84 | FYN (1.00) | FYNPIM1IKBKB | |
| SCHEMBL2946475 | 0.84 | FYN (0.79) | FYNPIM1NTRK1NTRK3NTRK2 | |
| SCHEMBL1202088 | 0.83 | FYN (0.63) | FYNPIM1NTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| WO-2007025090-A2 | HETEROBICYCLIC AND - TRICYCLIC INHIBITORS OF MAPK/ERK KINASE | KALYPSYS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | KALYPSYS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | KALYPSYS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | KALYPSYS, INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | FYN 421/4885PIM1 365/4885NTRK1 486/4885 |
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | MAPK1, MAP3K1, MAP3K6 | FYN 322/4885PIM1 157/4885NTRK1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.